Skip to main content
Premium Trial:

Request an Annual Quote

NCCN Recommends Testing for KRAS Mutation Before Treating Colorectal Cancer

NEW YORK (GenomeWeb News) – The National Comprehensive Cancer Network has updated its guidelines to recommend that oncologists determine the KRAS gene status of either a primary tumor or a metastasizing site as part of pre-treatment work-up for patients diagnosed with colon cancer.
 
The NCCN, a non-profit organization comprising 21 cancer centers, also recommended that only those patients with tumors characterized by the wild-type KRAS gene be treated with certain epidermal growth factor receptor inhibitor drugs including Bristol-Myers Squibb’s Erbitux and Amgen's Vectibix.
 
NCNN said that the recommendations in its updated Colon and Rectal Cancer Guidelines were in response to “a number of recent studies” showing that the KRAS gene status can help predict the outcome of anti-EGFR therapies.
 
For example, at the annual American Society of Clinical Oncology conference in June, researchers from the University Hospital Gasthuisberg in Leuven, Belgium, discussed a 587-patient study that found that 59.3 percent of patients with the wild-type KRAS gene responded to treatment with Erbitux and chemotherapy, compared to 43.2 percent of patients who responded to chemotherapy alone.
 
Diagnostic tests for KRAS status are currently made by DxS, TrimGen, Response Genetics, and Caris Diagnostics.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.